Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Inherited human CARD9 deficiency impairs lymphoid cell, but not fibroblast, IL-17–mediated immunity
Erika Della Mina, Carlos G. El-Haddad, Timothy A. West, Clara W.T. Chung, Jing Jing Li, Vivienne Lea, Elissa K. Deenick, Filomeen Haerynck, Jean-Laurent Casanova, Anne Puel, Cindy S. Ma, Stuart G. Tangye, Alisa Kane
Erika Della Mina, Carlos G. El-Haddad, Timothy A. West, Clara W.T. Chung, Jing Jing Li, Vivienne Lea, Elissa K. Deenick, Filomeen Haerynck, Jean-Laurent Casanova, Anne Puel, Cindy S. Ma, Stuart G. Tangye, Alisa Kane
View: Text | PDF
Research Article Genetics Immunology Infectious disease

Inherited human CARD9 deficiency impairs lymphoid cell, but not fibroblast, IL-17–mediated immunity

  • Text
  • PDF
Abstract

Nearly 100 individuals have been identified who carry deleterious biallelic germline variants in CARD9 and experience life-threatening, invasive fungal infections caused by Ascomycetes but are otherwise resistant to other infectious agents. CARD9 is an adaptor protein expressed predominantly in myeloid cells, which functions downstream of dectin receptors, pattern recognition receptors for fungal antigens, to activate innate immune responses. The impact of CARD9 deficiency on lymphocytes, however, is less clear. We deciphered the functional consequences and delineated mechanisms of disease in a patient (P1) with a nonsense germline homozygous CARD9 variant (c.673A>T/p.K225*) and invasive Candida disease. P1’s PBMCs expressed truncated CARD9 and showed significantly reduced cytokine production in response to fungal ligands. P1 had reduced frequencies of circulating memory CD4+ TH17-like (CCR6+CXCR3–) cells. In addition, in vitro differentiation of P1’s naive CD4+ T cells into IL-17A/IL-17F–secreting cells was greatly impaired. Consistent with impaired responses of innate and adaptive immune cells from P1 in vitro, proportions of Candida-specific CD4+ T cells were strongly and selectively diminished. Our findings suggest that the CARD9 variant identified in P1 is pathogenic, affecting not only CARD9-induced immunity mediated by myeloid cells but also CD4+ T cell–intrinsic IL-17–dependent immunity and Candida-specific T cell responses.

Authors

Erika Della Mina, Carlos G. El-Haddad, Timothy A. West, Clara W.T. Chung, Jing Jing Li, Vivienne Lea, Elissa K. Deenick, Filomeen Haerynck, Jean-Laurent Casanova, Anne Puel, Cindy S. Ma, Stuart G. Tangye, Alisa Kane

×

Figure 3

CARD9 K225* affects the frequency of memory CD4+ TH17 cells.

Options: View larger image (or click on image) Download as PowerPoint
CARD9 K225* affects the frequency of memory CD4+ TH17 cells.
PBMCs from ...
PBMCs from HDs (n = 15, white bars), from the heterozygous P1’s mother (CARD9 K225*/WT, red circles among HDs), from the patient with homozygous CARD9 K225* variant (P1, light gray bars), and from previously reported in the literature P2 and P3 (CARD9 Q289*/Q289*, dark gray bars, rhombus and square, respectively) were stained to determine the proportions of (A) T cells (CD3+), B cells (CD20+), and NK cells (CD56+); (B) MAIT (CD3+CD161+TCR-Vα7.2+) cell frequency; (C) CD4+ helper (CD4+ CD8–) and CD8+ cytotoxic (CD4–CD8+) T cell frequency; (D) CD4+ helper T cell subsets: naive (CD4+CCR7+CD45RA+), central memory (TCM, CD4+CCR7+CD45RA–), effector memory (TEM, CD4+CCR7–CD45RA–); (E) CD8+ cytotoxic T cells subsets: naive (CD8+ CCR7+CD45RA+), TCM (CD8+ CCR7+CD45RA–), TEM (CD8+ CCR7–CD45RA–), effector revertant memory (TEMRA, CD8+ CCR7–CD45RA+). (F) Representative contour plots gated on P1 showing frequency of Tregs (CD25hiCD127lo) (left panel) and proportion of Tregs (CD25hiCD127lo) in HDs, P1’s mother, P1–P5 (right panel). (G) Representative contour plots gated on P1 showing Tfh frequency (CD25lo/–CXCR5+CD45RA–) (left panel) and corresponding histograms showing Tfh proportion in HDs, P1’s mother, P1–P5 (right panel). (H) Representative contour plots gated on 1 HD and P1 showing frequency of TH1 (CD25lo/–CXCR5–CD45RA–CXCR3+CCR6–), TH17 (CD25lo/– CXCR5–CD45RA–CXCR3–CCR6+), TH2/9 (CD25lo/–CXCR5–CD45RA–CXCR3–CCR6), TH1/17 (CD25lo/–CXCR5–CD45RA–CXCR3+CCR6+) (left panel) and corresponding histograms showing proportion of TH1, TH17, TH2/9, TH1/17 in HDs, P1’s mother, P1, P2, and P3 (right panel). The data represent the mean ± SD of 6 independent experiments. *P < 0.05 using ANOVA or Kruskal-Wallis test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts